Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5821 AL 5835

Latino Alzheimer's disease caregivers and depression: using the stress coping model to examine the effects of spirituality and religion

Sun F, Hodge DR.

J Appl Gerontol. 2014 Apr;33(3):291-315. doi: 10.1177/0733464812444462. Epub 2012 May 15.

The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design

Devanand DP, Mintzer J, Schultz S, Sultzer D, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Andrews H, Levin B.

Am J Geriatr Psychiatry. 2012 Apr;20(4):362-73. doi: 10.1097/JGP.0b013e3182110563.

Experiences of supporting people with Down syndrome and Alzheimer's disease in aged care and family environments

Carling-Jenkins R, Torr J, Iacono T, Bigby C.

J Intellect Dev Disabil. 2012 Mar;37(1):54-60. doi: 10.3109/13668250.2011.645473. Epub 2012 Jan 3.

A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment

Amanzio M, Benedetti F, Vase L.

Int Psychogeriatr. 2012 May;24(5):698-707. doi: 10.1017/S1041610211002420. Epub 2012 Jan 4.

Withdrawal syndrome after donepezil cessation in a patient with dementia

Bidzan L, Bidzan M.

Neurol Sci. 2012 Dec;33(6):1459-61. doi: 10.1007/s10072-012-0938-8. Epub 2012 Jan 15.

A new frontier in spaced retrieval memory training for persons with Alzheimer's disease

Small JA.

Neuropsychol Rehabil. 2012;22(3):329-61. doi: 10.1080/09602011.2011.640468. Epub 2012 Jan 24.

Reducing the risk for Alzheimer's

Thomas SP.

Issues Ment Health Nurs. 2012 Feb;33(2):65. doi: 10.3109/01612840.2012.646211.

Citalopram for agitation in Alzheimer's disease: design and methods

Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group.

Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.

The role of S100a9 in the pathogenesis of Alzheimer's disease: the therapeutic effects of S100a9 knockdown or knockout

Chang KA, Kim HJ, Suh YH.

Neurodegener Dis. 2012;10(1-4):27-9. doi: 10.1159/000333781. Epub 2012 Feb 1.

A direct comparison of errorless and errorful therapy for object name relearning in Alzheimer's disease

Noonan KA, Pryer LR, Jones RW, Burns AS, Lambon Ralph MA.

Neuropsychol Rehabil. 2012;22(2):215-34. doi: 10.1080/09602011.2012.655002.

[Effects of a psychological group intervention on neuropsychiatric symptoms and communication in Alzheimer's dementia]

Fischer-Terworth C, Probst P.

Z Gerontol Geriatr. 2012 Jul;45(5):392-7. doi: 10.1007/s00391-012-0296-4.

[Psychotropic medication of elderly patients]

Kumagai R, Iseki E.

Nihon Rinsho. 2012 Jan;70(1):140-4.

[For an integrative approach of Alzheimer's disease. Relevance and limits]

Pierron-Robinet G.

Geriatr Psychol Neuropsychiatr Vieil. 2012 Mar;10(1):73-81. doi: 10.1684/pnv.2012.0321.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias